Trial Profile

Phase 1/2 study of ELU-42 for Wagner 1 and 2 Diabetic Foot Ulcers

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ELU 42 (Primary)
Indications Diabetic foot ulcer
Focus Adverse reactions; First in man

Most Recent Events

22 Jul 2025 New trial record
08 Jul 2025 According to an Eluciderm media release, data from this trial will establish the foundation of a Phase 2 clinical trial in 2026, with strong potential for a Breakthrough Therapy designation in early 2027.
08 Jul 2025 According to an Eluciderm media release, the study is set to begin the first week of August 2025 at three U.S. sites.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com